Immunome, Inc. (IMNM) shares jumped 20.44%, rising $4.00 to close at $23.57, following the company's announcement of positive topline results from its Phase 3 RINGSIDE trial evaluating varegacestat in patients with desmoid tumors.
The Phase 3 study met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in tumor volume versus placebo, along with favorable secondary outcomes.
The results position varegacestat as a potential best-in-class oral treatment for this rare and difficult-to-treat condition, and meaningfully de-risk the program ahead of potential regulatory discussions.
IMNM trades within a 52-week range of approximately $7.50 - $25.10.
The sharp move underscores investor optimism around varegacestat's commercial potential and Immunome's transition into a late-stage clinical company with a near-term regulatory catalyst.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.